Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic
An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Chao Lv
- Phone Number: +86 13810733217
- Email: chao.lv.cl1@hengrui.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Regularly taking any moderate-intensity or higher dose* of statin stabilization therapy for ≥4 weeks at screening:
- ASCVD risk is ultra-high risk Fasting LDL-C ≥ 1.4 mmol/L;
- ASCVD risk very high risk Fasting LDL-C ≥1.8 mmol/L;
- ASCVD risk is intermediate or high risk Fasting LDL-C ≥ 2.6 mmol/L.
Any other condition that is not met at screening Regularly taking any moderate intensity and higher dose* statin stabilization therapy for ≥4 weeks;
a) Fasting LDL-C ≥ 2.6 mmol/L.
- Fasting triglycerides ≤ 5.6 mmol/L.
Exclusion Criteria:
- Previously diagnosed type 1 diabetes or poorly controlled type 2 diabetes at screening (HbA1c > 8.5%).
- eGFR <30ml/min/1.73m2 at the screening visit.
- CK >5times ULN at the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SHR-1918
|
SHR-1918
|
|
Placebo Comparator: SHR-1918 placebo
|
SHR-1918 placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change in calculated LDL-C from baseline to week 16
Time Frame: from baseline to week 16
|
from baseline to week 16
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in calculated LDL-C from baseline to week 16
Time Frame: from baseline to week 16
|
from baseline to week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SHR-1918-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.